And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We look forward to another installment in our “Let’s-see-them-before-they-die” concert series, organize our library, and hang with our short person. And what about you? This remains a lovely time to enjoy the great outdoors. You could hunt for apples or pumpkins. Look ahead to a winter getaway. Or check to see how much health insurance you will have next year. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …
Avanir Pharmaceuticals (AVNR) is raking in hundreds of millions of dollars a year by aggressively targeting elderly nursing home residents for whom its Nuedextra pill may be unnecessary or even unsafe, CNN reports. The drug is approved to treat a disorder marked by sudden and uncontrollable laughing or crying, but not extensively studied in elderly patients. Since 2012, more than half of all Nuedexta pills have gone to long-term care facilities.
Allergan (AGN) reached a settlement with Pfizer’s (PFE) InnoPharma, one of four generic drug makers challenging the patents for its dry-eye medication Restasis in federal court, Reuters reports. As part of the deal, InnoPharma can sell a generic version in February 2024, or possibly earlier, about six months ahead of the scheduled patent expirations. Mylan, Teva Pharmaceuticals (TEVA), and Akorn are still contesting those patents in U.S. District Court in Texas.
As a frequent nursing home visitor what I’ve witnessed is uncontrollable staccato bursts of anger from the relatives who visit once a year from Florida and stay long enough to find fault in virtually everything.
Comments are closed.